ClinicalTrials.gg
Enrolling by invitationNCT05945225PRE-IOPUpdated Mar 18, 2026

Pregnancy Women and Individual Oral Prophylaxis in the Control of Gingival Inflammation (PRE-IOP)

An interventional study of Sonicare DiamondClean 9000 Philips® and HydroSonic Easy Curaden® in Pregnant Woman, sponsored by Claude Bernard University. Enrolling by invitation at 1 site in France. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by Claude Bernard University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

Gingivitis in pregnant women is a common inflammatory periodontal disease that appears from the third month of pregnancy with an overall prevalence of 35 to 100%. This condition is induced by oral biofilm and exacerbated by increased levels of sex steroid hormones characteristic of pregnancy. Strict bacterial plaque control with both professional and home oral hygiene is essential. Manual toothbrushes require a more specific manual technique for women, while sonic electric toothbrushes, due to their ease of use, might be an excellent for oral individual prophylaxis. Therefore, the question of which type of manual or electric toothbrush might be more effective in reducing gingival inflammation in pregnant women is still unresolved. In literature there are a large number of in vitro clinical studies on this topic, there are currently no clinical studies investigating this long-term clinical comparison.

In this context, this study is a randomized clinical trial consisting of a comparative evaluation between two manual and two sonic electric toothbrushes in the efficacy of the control of plaque in order to reduce gingivitis in women during the period of pregnancy.

02

Conditions studied

  • Pregnant Woman

Browse trials for

Keywords

  • manual toothbrush
  • electric sonic toothbrush
  • oral prophylaxis
  • pregnant woman
  • gingival inflammation
03

In context

Gingivitis

631 studies on the registry are indexed under Gingivitis; 107 are open to participants now.

This study's planned enrollment of 120 is above the median of 66 across 507 interventional studies indexed under Gingivitis.

Browse Gingivitis studies →

Lead sponsor

Claude Bernard University is the lead sponsor of 31 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female, 18 to 40 years of age
  • 15-18 weeks pregnant
  • Acceptance of study terms and conditions
  • Signature of form

Exclusion criteria

Exclusion Criteria:

  • Protected women
  • Stage II,III periodontal disease (i.e. PD ≥ 4 mm, and/or CAL ≥ 4 mm), generalized (>30% od sites)
  • History or treatment of periodontal disease
  • Current dental or orthodontic treatment
  • Fewer than 20 natural teeth, excluding third molars
  • Taking medication affecting the gums and/or oral mucosa
  • Regular use (more than once a week) of interdental brushes and/or dental floss and/or mouthwash
  • Removable prosthesis
  • Dental implants
  • Systemic disorder such as blood disorders, diabetes, and risk of endocarditis infections
  • Anticoagulant treatment
  • Inability to follow protocol or non-cooperation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Group using sonic toothbrush

    Patient will be asked to use a sonic toothbrush for 3 months

    Device: Sonicare DiamondClean 9000 Philips®

  • Experimental
    Group using hydrosonic toothbrush

    Patient will be asked to use a hydrosonic toothbrush for 3 months

    Device: HydroSonic Easy Curaden®

  • Experimental
    Group using manual toothbrush with 5460 strands

    Patients will be asked to use a manual toothbrush with 5460 strands for 3 months

    Device: Manual toothbrush Curaprox CS 5460

  • Placebo comparator
    Group using manual toothbrush

    Patients will be asked to use a manual toothbrush for 3 months

    Device: Manual toothbrush Oral-B 123

Interventions

  • DeviceSonicare DiamondClean 9000 Philips®

    Brush teeth with the electric toothbrush daily during 3 months

  • DeviceHydroSonic Easy Curaden®

    Brush teeth with the hydrosonic toothbrush daily during 3 months

  • DeviceManual toothbrush Oral-B 123

    Brush teeth with the manual toothbrush daily during 3 months

  • DeviceManual toothbrush Curaprox CS 5460

    Brush teeth with the manual toothbrush daily during 3 months

06

What researchers measure

Primary outcomes

  1. Incidence of gingival bleeding from baseline during woman pregnancy

    Change of gingival inflammation in pregnant woman using manual or electric toothbrushes in daily practice

    Time frame: T1 (Baseline), T2 (+ 1 month) and T3 (+ 3 months)

Secondary outcomes

  1. Effect on gingival bleeding

    Bleeding on Probing

    Time frame: T1 (Baseline), T2 (+ 1 month) and T3 (+ 3 months)

  2. Effect on gingival inflammation

    gingival index

    Time frame: T1 (Baseline), T2 (+ 1 month) and T3 (+ 3 months)

  3. Effect on dental plaque

    plaque index

    Time frame: T1 (Baseline), T2 (+ 1 month) and T3 (+ 3 months)

  4. Effect on gingival attachment

    clinical attachment loss

    Time frame: T1 (Baseline), T2 (+ 1 month) and T3 (+ 3 months)

  5. Effect on Periodontal Pocket

    Periodontal Pocket Probing Depth

    Time frame: T1 (Baseline), T2 (+ 1 month) and T3 (+ 3 months)

  6. Customer Satisfaction Score

    * the minimum and maximum values: 1, 7 * lower scores mean a worse outcome. * the minimum and maximum values: 1, 7 * lower scores mean a worse outcome. * the minimum and maximum values: 1, 7 * lower scores mean a worse outcome. The score range from 1 (minimum) to 7 (maximum). Lower score mean a worse outcome

    Time frame: T1 (Baseline), T2 (+ 1 month) and T3 (+ 3 months)

07

Study locations

1 site
  • Clinique Majorelle
    Nancy, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Dec 2026, 37 months after the start.

Of 204 non-industry interventional studies with no phase under Gingivitis, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 18. This study's planned 37 months is above that.

Counting every sponsor, half of 257 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2023
First posted
Jul 14, 2023
StartActual
Nov 1, 2023
Primary completionEst.
Dec 30, 2026
CompletionEst.
Sep 30, 2027
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05945225
Lead sponsor
Claude Bernard University
Collaborators
University of Nancy, Elsan
Responsible party
Carrouel Florence (Associate professor, Claude Bernard University) — Principal investigator
First posted
Jul 14, 2023
Start date
Nov 1, 2023
Primary completion
Dec 30, 2026 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Mar 18, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion